PaySign, Inc. Class B Stock News

Paysign posted strong Q2 2025 results, with 33% YoY revenue growth and robust Pharma segment momentum, driven by US tariffs and new client wins. PAYS is rated a hold, as the stock trades at fair value ($5.83), despite expected high demand for co-payment cards and expanded patient affordability programs. Pharma segment revenue surged 189% YoY, offsetting a 4.7% YoY decline in the core Plasma seg...

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. Appoints Jose Garcia as Executive Vice President, Life Science Solutions.

HENDERSON, Nev.--(BUSINESS WIRE)--Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions.

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. Opens 30,000 Square Foot Patient Service Support Center to Meet Growing Demand in Patient Affordability Business.

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. to Present at the Lake Street Best Ideas Growth BIG9 Conference.

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. Announces Election of Dan Henry as Chairman of the Board.

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. to Present at the Oppenheimer Technology, Internet & Communications Conference.

Paysign (PAYS) Q2 Revenue Jumps 33%